Feature

'I'm going to live forever': the guarantee-time bias

Author and Disclosure Information

 

Some study findings are more probably due to a bias in terms of who is included in the studies than to the miraculous effects of occupation, winning awards, or ER status, or whatever is being studied. How should investigators go about avoiding this bias, and more specifically, what should readers look for when they’re reading about some new miracle cure?

Click on the PDF icon above to read the full article.

Recommended Reading

Survey: Internists lack tools to care for survivors of childhood cancer
MDedge Hematology and Oncology
Bupropion-varenicline combo gave harder kick to smoking habits
MDedge Hematology and Oncology
Extracorporeal shock wave therapy promising for lymphedema
MDedge Hematology and Oncology
Low event rates with real-world use of rivaroxaban in NOAC
MDedge Hematology and Oncology
FDA: Stop prescribing combo drugs with high-dose acetaminophen
MDedge Hematology and Oncology
Vitamin D deficiency in the oncology setting
MDedge Hematology and Oncology
Understanding the experience of living with non–small-cell lung cancer (NSCLC): a qualitative study
MDedge Hematology and Oncology
Current options and future directions in the systemic treatment of metastatic melanoma
MDedge Hematology and Oncology
Biomarker testing for treatment of metastatic colorectal cancer: role of the pathologist in community practice
MDedge Hematology and Oncology
A look ahead for 2014
MDedge Hematology and Oncology